Scil Proteins Gmbh

Navigo Proteins Gmbh

Manja Gloser

Erik Fiedler

Markus Fiedler

Ulrich Haupts

Arnd Steuernagel

Eva Bosse-Doenecke

Joerg Nerkamp

Anja Kunert

Madlen Zwarg

Thomas Goettler

Ilka Haenssgen

Anja Katzschmann

Florian Settele

Ilka Haenßgen

The invention relates to fusion proteins comprising at least one extradomain B of fibronectin (ED-B) specific binding domain with high stability in serum and at least one APS domain essentially consisting of or consisting of up to about 80 amino acids selected from alanine, proline, serine, and optionally aspartic acid. The fusion protein further comprises at least one coupling site consisting of at least one cysteine. The invention relates to the use of the fusion proteins or of compositions comprising the fusion proteins for medical applications, such as diagnosis or treatment of cancer or cardiovascular diseases.

Fusion proteins with specificity for ED-B and long serum half-life for diagnosis or treatment of cancer

The present invention refers to novel hetero-multimeric proteins obtained from modified ubiquitin capable of binding the extradomain B of fibronectin (ED-B) with high affinity. Furthermore, the invention refers to fusion proteins comprising said recombinant protein fused to a pharmaceutically and/or diagnostically active component. The invention is further directed to the use of said proteins in medical treatment methods.

Modified ubiquitin proteins having a specific binding activity for the extradomain B of fibronectin

Growing community of inventors

Halle/Saale, Germany

Manja Gloser